AnalystBook Research · Company Intelligence

Cadre Holdings, Inc.

CDRENYSE

Built from Cadre Holdings, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Cadre grew revenue and cash flow, but debt rose and insiders were sellers.

The read at a glance✓ Audited against SEC data
  • Business mixSafety and survivability gearNote
  • Revenue$610.3M, +7.5%OK
  • Net income$44.1M, +22.2%OK
  • FCF$56.8M, +117.7%OK
  • Debt$291.0M, +37.4%Watch
  • Insiders0 purchases and 9 salesWatch
  • AccountingAltman grey; Beneish clean; EQ safeNote

Business

Cadre sells safety and survivability equipment for first responders, law enforcement, explosive ordnance disposal, nuclear safety, and related markets.

Where the revenue comes from

Fiscal 2025, as Cadre Holdings, Inc. reports it. History and quarterly detail are in the app.

  • Products$543.7M
  • Distribution Services$104.9M

Leadership changes

From Cadre Holdings, Inc.'s own filings, the day they're filed.

  • Nicholas Sokolow · Directors · departureeff. 2025-01-31
  • Gianmaria Delzanno · chairman · appointmenteff. 2025-01-13

Latest filings

  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-06-03
  • 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Cadre Holdings, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.